Aktie A12HVG PHARMACYTE BIOTECH, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen PharmaCyte Biotech, Inc. Other OTC

Aktien

A12HVG

US71715X1046

PMCB

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors
Femasys Inc. announces tranche update
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.
PharmaCyte Biotech : Change in Certifying Accountants - Form 8-K
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023
PharmaCyte Biotech : Certificate of Incorporation/Bylaws - Form 8-K
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on May 11, 2023.
PharmaCyte Biotech Announces Final Results of Tender Offer
PharmaCyte Biotech, Inc.'s Equity Buyback announced on May 11, 2023, has closed with 8,085,879 shares, representing 48.15% for $26.46 million.
PHARMACYTE BIOTECH, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CSPR Aktie
  4. A12HVG Aktie
  5. Nachrichten PharmaCyte Biotech, Inc.
  6. Andere Sprachen